Wall Street Analysts Predict a 54.95% Upside in Immatics (IMTX): Here's What You Should Know
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-
Memo Therapeutics AG Appoints Paul Carter as Chairperson
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market
Here's Why We Think Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Looks Fair for the Time Being
Key Insights Immatics' Annual General Meeting to take place on 20th of June CEO Harpreet Singh's total compensation includes salary of €488.0k Total compensation is similar to the industry average
We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring reve
12 Health Care Stocks Moving In Friday's Intraday Session
GainersInnovative Eyewear (NASDAQ:LUCY) shares increased by 328.8% to $0.8 during Friday's regular session. The market value of their outstanding shares is at $13.9 million. OneMedNet (NASDAQ:ONMD) sh
Here's Why We're Not Too Worried About Immatics' (NASDAQ:IMTX) Cash Burn Situation
Immatics Is Maintained at Buy by Mizuho
Immatics Is Maintained at Buy by Mizuho
Express News | Mizuho Maintains Buy on Immatics, Raises Price Target to $16
Immatics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 44.4% Mizuho $14 → $16 Maintains Buy 11/02/2023 — Cantor Fitzgerald Initiates Coverage On → Ov
Buy Rating Affirmed for Immatics on Strong TCR-T Cell Therapy Data and Promising Outlook
Express News | Immatics NV : Mizuho Raises Target Price to $16 From $14
Nearly 90% of patients have shrinking tumors! Immatics (IMTX.US) innovative cell therapy phase 2/3 trial is about to begin
iMA203 is a TCR-T cell developed by IMMatics' proprietary ActenGine platform and targets the melanoma antigen PRAME presented by HLA-A*02.
Immatics' Q1 Loss Narrows. Revenue Rises
Immatics (IMTX) reported a Q1 net loss Tuesday of 0.04 euros ($0.043) per diluted share, narrowing from a loss of 0.26 euros a year earlier. Three analysts polled by Capital IQ expected a loss of 0.27
6-K: Report of foreign private issuer (related to financial reporting)
Immatics: Runway Funding Company Operations Into 2027 >IMTX
Immatics: Runway Funding Company Operations Into 2027 >IMTX
Immatics 1Q Loss EUR3.05M >IMTX
Immatics 1Q Loss EUR3.05M >IMTX
Press Release: Immatics Announces First Quarter 2024 Financial Results and Business Update
Immatics Announces First Quarter 2024 Financial Results and Business Update Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine(R) IMA203 TCR-T Targeting PRAME
Immatics N.V.'s (NASDAQ:IMTX) Share Price Could Signal Some Risk
Immatics N.V.'s (NASDAQ:IMTX) price-to-sales (or "P/S") ratio of 19.3x might make it look like a sell right now compared to the Biotechs industry in the United States, where around half of the compan
Maintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising Partnerships